A new review by the Financial Crimes Commission (FCC) has identified significant weaknesses in the systems used to regulate the importation and monitoring of controlled pharmaceutical substances within the Department of Health and Human Services' pharmaceutical division. The findings are detailed in the Commission's Financial Crimes Prevention Review, launched as part of its broader efforts to combat financial crime and improve regulatory oversight.

The review was initiated following concerns over possible corrupt practices involving the distribution of pregabalin, a regulated medication. Investigators examined the procedures used to manage pharmaceutical imports and found several areas where existing controls could be strengthened.

According to the report, many regulatory processes still depend heavily on paper-based documentation and manual handling, increasing the likelihood of administrative errors, missing records, and reduced accountability. The FCC also highlighted limited coordination between government departments and insufficient oversight, making it more difficult to consistently enforce existing regulations.

One of the report's key concerns involves the management of pharmaceutical import quotas. Investigators found instances of poorly documented quota adjustments and incomplete record-keeping, creating challenges in tracking regulated medicines from importation through to distribution. These shortcomings reduce transparency and make it more difficult to detect irregularities within the supply chain.

The Commission further warned that the absence of secure digital systems and gaps in compliance procedures create opportunities for misconduct. Potential risks identified include document fraud, manipulation of import quotas, unauthorized approvals, bribery involving public officials, and the diversion of regulated medicines into unauthorized or illegal markets.

To strengthen oversight, the FCC recommends a comprehensive reform of the governance framework, including clearer responsibilities for regulatory agencies and closer collaboration among all stakeholders involved in pharmaceutical oversight. The report also calls for stricter quota management based on transparent and verifiable criteria, as well as stronger inspections at ports of entry.

A major recommendation is the full digitization of the import approval and monitoring process for controlled medicines. According to the Commission, modern digital systems would improve product traceability, enhance operational transparency, and reduce opportunities for fraud.

The FCC concludes that without substantial reforms, existing weaknesses could continue to expose the pharmaceutical sector to financial crime, regulatory failures, and potential risks to public health.